TScan Therapeutics (NASDAQ:TCRX) Rating Reiterated by Wedbush

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a research note issued on Wednesday, RTT News reports. They presently have a $10.00 target price on the stock. Wedbush’s price objective suggests a potential upside of 44.51% from the stock’s previous close. Wedbush also issued estimates for TScan Therapeutics’ Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.28) EPS and Q4 2025 earnings at ($0.27) EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a report on Thursday, March 7th.

TScan Therapeutics Stock Performance

Shares of TCRX stock opened at $6.92 on Wednesday. The firm has a 50-day moving average of $7.04 and a 200-day moving average of $5.64. The company has a market cap of $331.33 million, a P/E ratio of -3.66 and a beta of 0.90. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.51 and a quick ratio of 6.51. TScan Therapeutics has a one year low of $1.62 and a one year high of $9.00.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Wednesday, March 6th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. The company had revenue of $7.21 million during the quarter, compared to the consensus estimate of $2.94 million. TScan Therapeutics had a negative net margin of 423.86% and a negative return on equity of 60.65%. Equities research analysts forecast that TScan Therapeutics will post -1.04 EPS for the current fiscal year.

Institutional Trading of TScan Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Cannon Global Investment Management LLC purchased a new stake in TScan Therapeutics during the first quarter worth about $139,000. Vanguard Group Inc. increased its holdings in TScan Therapeutics by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 1,788,152 shares of the company’s stock worth $10,425,000 after buying an additional 35,558 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of TScan Therapeutics in the fourth quarter worth about $177,000. Virtu Financial LLC purchased a new position in shares of TScan Therapeutics in the fourth quarter worth about $107,000. Finally, Balyasny Asset Management L.P. purchased a new position in shares of TScan Therapeutics in the fourth quarter worth about $268,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.